BALANCE is a clinical study of an investigational antisense drug for treating Familial Chylomicronemia Syndrome (FCS). The study will help determine the safety and effectiveness of the potential new treatment. The drug is an antisense therapy for Familial Chylomicronemia Syndrome (FCS), and is designed to target and reduce the activity of a protein in the body. Targeting this protein may help break down dietary fat that can lower triglycerides in the blood and potentially help improve a patient’s quality of life for people living with FCS.
Would you like to know more about the BALANCE study?